サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1785912

がん生物学的療法の世界市場

Cancer Biological Therapy

出版日
ページ情報
英文 211 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.84円
がん生物学的療法の世界市場
出版日: 2025年08月07日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 211 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

がん生物学的療法の世界市場は2030年までに1,731億米ドルに達する見込み

2024年に1,219億米ドルと推定されるがん生物学的療法の世界市場は、2030年には1,731億米ドルに達し、分析期間2024-2030年のCAGRは6.0%で成長すると予測されます。本レポートで分析したセグメントの一つであるモノクローナル抗体は、CAGR 6.9%を記録し、分析期間終了時には699億米ドルに達すると予測されます。がん成長阻害剤セグメントの成長率は、分析期間中CAGR 5.9%と推定されます。

米国市場は332億米ドルと推定、中国はCAGR 9.6%で成長予測

米国のがん生物学的療法市場は、2024年に332億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに355億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは9.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.9%と6.0%と予測されています。欧州では、ドイツがCAGR 4.0%で成長すると予測されています。

世界の「がん生物学的療法」市場- 主要動向と促進要因のまとめ

生物学的療法はがん治療のパラダイムをどう変革するか？

がん生物学的療法は、従来の化学療法から、より標的を絞った免疫ベースのアプローチへの極めて重要な転換を意味し、がん細胞と闘うために身体の自然なメカニズムや人工の生物学的薬剤を活用します。これらの治療法には、モノクローナル抗体、サイトカイン療法、がんワクチン、腫瘍溶解性ウイルス、CAR-T細胞療法などが含まれます。細胞毒性薬とは異なり、生物学的療法は精密な標的を提供するため、健康な組織への付随的なダメージを軽減し、患者のQOLを向上させる可能性があります。世界のがん罹患率の上昇に伴い、特に難治性がんや転移性がんに対しては、広範なスペクトルを持つ選択肢を超える治療が急務となっています。生物学的製剤は、リンパ腫、黒色腫、乳がん、肺がんを含む様々な悪性腫瘍に有効であることが証明されつつあります。診断学とバイオマーカーが治療決定に統合されたことで、生物学的療法を遺伝子プロファイルに合わせて調整することが可能になり、その成功率は高まっています。チェックポイント阻害剤とモノクローナルを含む併用療法もまた、新たなフロンティアを開いています。さらに、生物学的療法の重要なサブセットである免疫療法は、多くの国で急速に第一選択となりつつあり、がん治療戦略の根本的な進化を示しています。

生物学的製剤の治療範囲を拡大する科学的イノベーションとは？

がん生物学的療法の状況は、細胞工学、遺伝子編集、抗体開発における画期的な進歩によって再定義されつつあります。がん細胞とT細胞に同時に結合できる二重特異性抗体の出現は、強力な新しい治療法を生み出しつつあります。CAR-T細胞療法は、当初は血液悪性腫瘍に使用されていたが、腫瘍標的化技術や持続性技術の改良により、固形がんにも適応されつつあります。腫瘍特異的変異に対する免疫認識を高めるために、個別化新抗原ワクチンが開発されています。合成生物学は、安全スイッチや二重機能機構を組み込んだプログラム可能な免疫細胞を可能にしています。CRISPR遺伝子編集は、養子細胞療法の性能を高め、腫瘍による免疫逃避を最小限に抑えるために用いられています。さらに、タンパク質工学の進歩により、高い特異性と強力な細胞毒性を併せ持つ抗体薬物複合体（ADC）が生み出されつつあります。AIによる予測モデリングは、最適化された薬物動態と最小限の毒性を持つ生物製剤の設計を容易にしています。これらの技術革新は、治療可能ながんの種類を拡大するだけでなく、これまで以上に迅速で、費用対効果が高く、標的を絞った治療開発を可能にしています。

規制の変化と患者の要望は、がん生物学的製剤をどのように変えているのか？

がん生物学的製剤の規制状況は、FDAの画期的治療薬（Breakthrough Therapy）やEMAのプライム指定（PRIME）のような、より迅速な承認への道筋をもたらし、技術革新と歩調を合わせるように変化しています。チェックポイント阻害剤やCAR-T療法などの早期承認は、これらの治療の緊急性と影響力を強調しています。しかし、生物製剤は複雑で新規性が高いため、規制当局も厳しい市販後調査や実臨床でのエビデンスを要求しています。患者アドボカシーは治療アクセスを形成する力となっており、最先端治療への助成や償還を求めるヘルスケアシステムへの圧力が高まっています。価値ベースのヘルスケアの台頭は、生物製剤の償還についてアウトカムベースのモデルを評価するよう支払者に促しています。これと並行して、臨床試験における多様性が重視されるようになってきており、特に免疫療法は集団によって挙動が異なる可能性があります。遺伝子組換え療法に関する倫理的配慮も、製造や同意プロトコールにおける監視の厳格化につながっています。さらに、治療法の選択におけるコンパニオン診断薬の役割の高まりは、生物製剤企業が診断薬企業と緊密に提携し、バイオマーカー主導の戦略を共同開発することを後押ししています。このような全体的な規制と患者のダイナミズムは、より高い透明性と安全性を要求する一方で、イノベーションを加速させています。

がん生物学的療法市場の成長はいくつかの要因によって牽引される

がん罹患率の上昇、個別化医療の採用拡大、免疫がんパイプラインへの投資拡大などです。治療が困難ながん、特に標準的な化学療法や放射線療法に耐性のあるがんでは、生物学的製剤の需要が急増しています。PD-1/PD-L1阻害剤とCAR-T細胞製品の成功は、次世代免疫療法へのバイオテクノロジーと製薬企業の投資の波に拍車をかけた。製薬大手は買収を通じて生物学的ポートフォリオを拡大し、政府は官民パートナーシップを通じてがん研究に資金を提供しています。開発途上地域では、ヘルスケアのインフラ整備が進み、認知度の向上や早期診断の取り組みに支えられ、先進的治療へのアクセスが増加しています。消費者行動の動向から、患者は副作用が少なく寛解期間が長い治療法を求めるようになっています。アジア太平洋を中心とした世界の臨床試験の拡大は、新たながんサブタイプや適応症への生物学的製剤の参入を促進しています。テレオンコロジーとデジタルヘルスプラットフォームは、患者管理とフォローアップを強化し、生物学的製剤のアドヒアランスと転帰の追跡をサポートしています。これらの促進要因が相まって、がん生物学的療法市場の継続的な進化に向けた強固な基盤が形成されつつあります。

セグメント

製品（モノクローナル抗体、がん成長阻害剤、血球成長因子、サイトカイン、ワクチン）;投与経路（経口投与、注射投与）

調査対象企業の例

  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Seattle Genetics, Inc.（Seagen Inc.）
  • Takeda Pharmaceutical Company Limited

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP29768

Global Cancer Biological Therapy Market to Reach US$173.1 Billion by 2030

The global market for Cancer Biological Therapy estimated at US$121.9 Billion in the year 2024, is expected to reach US$173.1 Billion by 2030, growing at a CAGR of 6.0% over the analysis period 2024-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$69.9 Billion by the end of the analysis period. Growth in the Cancer Growth Blockers segment is estimated at 5.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$33.2 Billion While China is Forecast to Grow at 9.6% CAGR

The Cancer Biological Therapy market in the U.S. is estimated at US$33.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$35.5 Billion by the year 2030 trailing a CAGR of 9.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 6.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.0% CAGR.

Global "Cancer Biological Therapy" Market - Key Trends & Drivers Summarized

How Is Biological Therapy Transforming The Cancer Treatment Paradigm?

Cancer biological therapy represents a pivotal shift from traditional chemotherapies to more targeted and immune-based approaches, leveraging the body's natural mechanisms or engineered biological agents to combat cancer cells. These therapies include monoclonal antibodies, cytokine therapies, cancer vaccines, oncolytic viruses, and CAR-T cell therapies. Unlike cytotoxic drugs, biological therapies offer precision targeting, potentially reducing collateral damage to healthy tissues and improving patient quality of life. With rising global cancer incidence, there's a pressing need for treatments that go beyond broad-spectrum options-particularly for refractory and metastatic cancers. Biologics are proving effective across a range of malignancies including lymphomas, melanoma, breast cancer, and lung cancer. The integration of diagnostics and biomarkers into treatment decisions has enabled biological therapies to be tailored to genetic profiles, increasing their success rates. Combination therapies involving checkpoint inhibitors and monoclonals are also opening new frontiers. Moreover, immunotherapy-an important subset of biological therapy-is rapidly becoming a first-line option in many countries, signaling a fundamental evolution in oncology treatment strategy.

What Scientific Innovations Are Expanding The Therapeutic Reach Of Biologics?

The cancer biological therapy landscape is being redefined by breakthroughs in cell engineering, genetic editing, and antibody development. The advent of bispecific antibodies, which can simultaneously bind to cancer cells and T-cells, is creating potent new treatment modalities. CAR-T cell therapy, initially used in hematologic malignancies, is being adapted for solid tumors through improved tumor-targeting and persistence technologies. Personalized neoantigen vaccines are being developed to boost immune recognition of tumor-specific mutations. Synthetic biology is enabling programmable immune cells with built-in safety switches and dual-function mechanisms. CRISPR gene editing is being used to enhance the performance of adoptive cell therapies, minimizing immune escape by tumors. Additionally, advances in protein engineering are yielding antibody-drug conjugates (ADCs) that combine high specificity with powerful cytotoxic payloads. AI-driven predictive modeling is facilitating the design of biologics with optimized pharmacokinetics and minimal toxicity. These innovations are not just expanding the types of cancers that can be treated but are also enabling therapy development that is faster, more cost-effective, and more targeted than ever before.

How Are Regulatory Shifts And Patient Demands Reshaping Cancer Biologics?

The regulatory landscape for cancer biological therapies is undergoing transformation to keep pace with innovation, leading to faster approval pathways like FDA’s Breakthrough Therapy and EMA’s PRIME designations. Accelerated approvals for drugs such as checkpoint inhibitors and CAR-T therapies underscore the urgency and impact of these treatments. However, regulators are also enforcing stringent post-market surveillance and real-world evidence requirements due to the complexity and novelty of biologics. Patient advocacy has become a force in shaping treatment access, with increasing pressure on healthcare systems to subsidize or reimburse cutting-edge therapies. The rise of value-based healthcare is prompting payers to assess outcomes-based models for biologics reimbursement. In parallel, there's increasing emphasis on diversity in clinical trials, particularly for immunotherapies, which can behave differently across populations. Ethical considerations around gene-modified therapies are also leading to stricter oversight in manufacturing and consent protocols. Furthermore, the growing role of companion diagnostics in therapy selection is pushing biologics companies to partner closely with diagnostic firms to co-develop biomarker-led strategies. This holistic regulatory-patient dynamic is accelerating innovation while demanding higher transparency and safety.

The Growth In The Cancer Biological Therapy Market Is Driven By Several Factors…

…including rising cancer prevalence, increased adoption of personalized medicine, and growing investment in immuno-oncology pipelines. Demand is surging for biologics in difficult-to-treat cancers, particularly those resistant to standard chemotherapy or radiation. The success of PD-1/PD-L1 inhibitors and CAR-T cell products has spurred a wave of biotech and pharma investment in next-gen immunotherapies. Pharmaceutical giants are expanding their biological portfolios through acquisitions, while governments are funding cancer research through public-private partnerships. In developing regions, the rollout of healthcare infrastructure is increasing access to advanced therapies, supported by rising awareness and early diagnosis initiatives. Trends in consumer behavior show patients increasingly seeking therapies with fewer side effects and longer remission durations. The expansion of clinical trials globally, especially in Asia-Pacific, is facilitating the entry of biologics into new cancer subtypes and indications. Tele-oncology and digital health platforms are enhancing patient management and follow-up, supporting biologic adherence and outcomes tracking. Together, these drivers are forging a robust foundation for the continued evolution of the cancer biological therapy market.

SCOPE OF STUDY:

The report analyzes the Cancer Biological Therapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines, Vaccines); Administration Route (Oral Administration, Injectable Administration)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Seattle Genetics, Inc. (Seagen Inc.)
  • Takeda Pharmaceutical Company Limited

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Cancer Biological Therapy - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Preference for Targeted Therapies Over Conventional Chemotherapy
    • Rising Approvals and Pipeline Expansion of Monoclonal Antibody Treatments
    • Increased Investment in Immunotherapy Research Boosting Market Innovation
    • Adoption of CAR-T Cell Therapy Driving Personalized Medicine Adoption
    • Surge in Demand for Checkpoint Inhibitors Across Multiple Cancer Types
    • Advancements in Biomarker and Companion Diagnostic Technologies Supporting Targeted Therapy
    • Increasing Role of Biopharmaceutical Companies in Cancer Therapeutics Development
    • Expansion of Biosimilars and Biobetters Enhancing Market Accessibility
    • Growing Use of Combination Biological Therapies for Enhanced Efficacy
    • Rising Patient Demand for Less Invasive and More Tolerable Treatment Options
    • Rapid Uptake of Precision Oncology Creating Opportunities for Biological Agents
    • Emergence of Neoantigen-Based Therapies and Cancer Vaccines Fueling Research
    • Improved Clinical Outcomes Supporting Shift Toward Biologic-Based Cancer Care
    • Government and Private Funding in Oncology Driving Clinical Trial Acceleration
    • Increased Collaboration Between Diagnostic and Therapeutic Players Enabling Personalized Approaches
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Cancer Biological Therapy Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Cancer Biological Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Cancer Biological Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Monoclonal Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Cancer Growth Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Cancer Growth Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Blood Cell Growth Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Blood Cell Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Cytokines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Cytokines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Injectable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Injectable Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Cancer Biological Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 18: USA Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 19: USA 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
  • CANADA
    • TABLE 22: Canada Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 23: Canada 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
    • TABLE 24: Canada Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 25: Canada 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
  • JAPAN
    • Cancer Biological Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 26: Japan Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Japan 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
    • TABLE 28: Japan Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: Japan 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
  • CHINA
    • Cancer Biological Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 30: China Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: China 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
    • TABLE 32: China Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: China 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
  • EUROPE
    • Cancer Biological Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 34: Europe Recent Past, Current & Future Analysis for Cancer Biological Therapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 35: Europe 6-Year Perspective for Cancer Biological Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 36: Europe Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Europe 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Europe 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
  • FRANCE
    • Cancer Biological Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 40: France Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: France 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
    • TABLE 42: France Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: France 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
  • GERMANY
    • Cancer Biological Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 44: Germany Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Germany 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
    • TABLE 46: Germany Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Germany 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
  • ITALY
    • TABLE 48: Italy Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Italy 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
    • TABLE 50: Italy Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Italy 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
  • UNITED KINGDOM
    • Cancer Biological Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 52: UK Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: UK 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
    • TABLE 54: UK Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: UK 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
  • SPAIN
    • TABLE 56: Spain Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Spain 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
    • TABLE 58: Spain Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Spain 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
  • RUSSIA
    • TABLE 60: Russia Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Russia 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
    • TABLE 62: Russia Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Russia 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 64: Rest of Europe Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Rest of Europe 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
    • TABLE 66: Rest of Europe Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Rest of Europe 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Cancer Biological Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 68: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biological Therapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Asia-Pacific 6-Year Perspective for Cancer Biological Therapy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2025 & 2030
    • TABLE 70: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Asia-Pacific 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
    • TABLE 72: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Asia-Pacific 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
  • AUSTRALIA
    • Cancer Biological Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 74: Australia Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Australia 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
    • TABLE 76: Australia Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Australia 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
  • INDIA
    • Cancer Biological Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 78: India Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: India 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
    • TABLE 80: India Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: India 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
  • SOUTH KOREA
    • TABLE 82: South Korea Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: South Korea 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
    • TABLE 84: South Korea Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: South Korea 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 86: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Asia-Pacific 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
    • TABLE 88: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Rest of Asia-Pacific 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
  • LATIN AMERICA
    • Cancer Biological Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 90: Latin America Recent Past, Current & Future Analysis for Cancer Biological Therapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 91: Latin America 6-Year Perspective for Cancer Biological Therapy by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2025 & 2030
    • TABLE 92: Latin America Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Latin America 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
    • TABLE 94: Latin America Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Latin America 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
  • ARGENTINA
    • TABLE 96: Argentina Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Argentina 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
    • TABLE 98: Argentina Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Argentina 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
  • BRAZIL
    • TABLE 100: Brazil Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Brazil 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
    • TABLE 102: Brazil Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Brazil 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
  • MEXICO
    • TABLE 104: Mexico Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Mexico 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
    • TABLE 106: Mexico Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Mexico 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 108: Rest of Latin America Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 109: Rest of Latin America 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
    • TABLE 110: Rest of Latin America Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Rest of Latin America 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
  • MIDDLE EAST
    • Cancer Biological Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 112: Middle East Recent Past, Current & Future Analysis for Cancer Biological Therapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 113: Middle East 6-Year Perspective for Cancer Biological Therapy by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2025 & 2030
    • TABLE 114: Middle East Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 115: Middle East 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
    • TABLE 116: Middle East Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Middle East 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
  • IRAN
    • TABLE 118: Iran Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Iran 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
    • TABLE 120: Iran Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Iran 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
  • ISRAEL
    • TABLE 122: Israel Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Israel 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
    • TABLE 124: Israel Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 125: Israel 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
  • SAUDI ARABIA
    • TABLE 126: Saudi Arabia Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 127: Saudi Arabia 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
    • TABLE 128: Saudi Arabia Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Saudi Arabia 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 130: UAE Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 131: UAE 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
    • TABLE 132: UAE Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 133: UAE 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 134: Rest of Middle East Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Middle East 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
    • TABLE 136: Rest of Middle East Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 137: Rest of Middle East 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
  • AFRICA
    • Cancer Biological Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 138: Africa Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 139: Africa 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
    • TABLE 140: Africa Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Africa 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030

IV. COMPETITION